Investigating how FOSL1 affects cancer stem cells in head and neck cancer treatment

Who could benefit from this research

What this research studies

This research focuses on understanding the role of FOSL1 in head and neck squamous cell carcinoma (HNSCC) and its relationship with the chemotherapeutic drug cisplatin. The study aims to identify how FOSL1 super-enhancers contribute to the survival and resistance of cancer stem cells (CSCs) to cisplatin treatment. By exploring the mechanisms behind FOSL1's influence on CSCs, the researchers hope to develop targeted therapies that can overcome cisplatin resistance, potentially improving treatment outcomes for patients. The approach includes using advanced techniques to analyze the genetic and functional properties of these cancer cells.

Why it matters

Where this research is happening

• Virginia Commonwealth University
  Richmond, United States Active

Researchers

• Principal investigator: Li, Jiong — Virginia Commonwealth University
• Study coordinator: Li, Jiong

Related research

Other NIH-funded projects on the same topics.

• Lymph node metastasis and immune tolerance in head and neck cancer

  A study in people with head and neck cancer looks at how cancer spread to lymph nodes may shape the immune system and help tumors grow.

  NIH research Stanford University · Stanford, United States · NIH-11614785

• Restoring responses to immunotherapy in metastatic lymph nodes in head and neck cancer

  A clinical research project aims to improve how immunotherapy works when cancer has spread to lymph nodes in head and neck cancer patients.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11510384

• Data-driven classification of aggressive tissue traits to predict cancer outcomes in HPV-negative head and neck cancer

  A clinician-science grant uses data science and AI to identify tissue patterns in HPV-negative head and neck cancer that may predict how long patients stay cancer-free.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11505841

• HNSCC, iron addiction, and potential iron-targeted therapies

  This grant explores how head and neck cancer cells become dependent on iron and whether targeting iron pathways could lead to new treatments for patients with recurrent or metastatic disease.

  NIH research Virginia Commonwealth University · Richmond, United States · NIH-11441057

• Targeting SREBP2 to boost radiation therapy in HPV-negative head and neck cancer

  This grant aims to see if blocking SREBP2 can make radiation therapy work better for people with HPV-negative Head and Neck Squamous Cell Carcinoma.

  NIH research Indiana University Indianapolis · Indianapolis, United States · NIH-11427724

• Axelopran added to pembrolizumab for frontline recurrent/metastatic head and neck cancer

  A new treatment approach combines axelopran with pembrolizumab for people with PD-L1 positive recurrent/metastatic head and neck cancer to see if it improves response.

  NIH research Glycyx Mor, INC. · San Francisco, United States · NIH-11418514

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.